# Tiba Biotech

> Tiba Biotech is a Cambridge, Massachusetts preclinical biotech spun out of MIT and the Whitehead Institute that is building a new generation of RNA vaccines and therapeutics. Its RNABL platform swaps the fragile lipid nanoparticles behind first-generation mRNA shots for fully synthetic, biodegradable dendrimer nanoparticles that carry larger RNA payloads with less toxicity and gentler cold-chain demands. The company is applying the technology across human vaccines, cancer immunotherapy, gene editing delivery, and animal health, backed by CEPI, BARDA, the NIH, and the NCI.

- **Founded:** 2018
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Karl Ruping (Co-Founder & CEO), Jasdave Chahal (Co-Founder & Chief Scientific Officer), Omar F. Khan (Co-Founder), Christian W. Mandl (Co-Founder), Peter McGrath (Co-Founder & Head of Animal Health)
- **Team size:** ~19 employees
- **Products:** RNABL Delivery Platform, RNA Vaccines, RNA Cancer Immunotherapies, Gene Therapy & Gene Editing Delivery, Animal Health Vaccines
- **Notable:** Designed a Zika virus vaccine candidate for the U.S. Army in seven days (March 2017)., Origin science published in a 2016 paper on RNA nanoparticle vaccines from MIT/Whitehead., Issued U.S. Patent No. 10,548,959 (February 2020) covering its nanoparticle technology.

## Products & services

- **RNABL Delivery Platform** — A fully synthetic, biodegradable dendrimer nanoparticle (roughly 100-150nm) that complexes and delivers RNA. It carries larger and more complex RNA payloads than lipid nanoparticles, reduces dose-limiting toxicity and inflammation, and relaxes cold-chain requirements.
- **RNA Vaccines** — Prophylactic RNA vaccines for seasonal and pandemic influenza and other infectious diseases, including work under the NIH CIVICs universal flu program and a CEPI 'Disease X' preparedness study.
- **RNA Cancer Immunotherapies** — Tissue-targeted delivery paired with enhanced self-amplifying RNA payloads for immuno-oncology, advanced under an NCI SBIR award.
- **Gene Therapy & Gene Editing Delivery** — Use of the RNABL platform to deliver RNA for gene therapy and gene-editing applications.
- **Animal Health Vaccines** — RNA vaccines for livestock and zoonotic disease, including a livestock vaccine manufactured in New South Wales, Australia and a BARDA-backed swine flu / influenza therapeutic program.

## Achievements

- Designed a Zika virus vaccine candidate for the U.S. Army in seven days (March 2017).
- Origin science published in a 2016 paper on RNA nanoparticle vaccines from MIT/Whitehead.
- Issued U.S. Patent No. 10,548,959 (February 2020) covering its nanoparticle technology.
- Selected into the NIH CIVICs universal influenza vaccine initiative (2021).
- Demonstrated nasal delivery of RNABL nanoparticles (December 2022).
- Won a $2M CEPI partnership to prepare for 'Disease X' (2023).
- Manufactured its first livestock vaccine in New South Wales, Australia (May 2024).
- Received a BARDA FASTx award (July 2024) and an NCI SBIR award for cancer immunotherapy.

## Latest updates

- **2024-07** — Received a BARDA FASTx award to advance RNA-based influenza therapeutics.
- **2024-05** — Manufactured its first livestock RNA vaccine in New South Wales, Australia.
- **2024-01** — Awarded an NCI SBIR grant to develop next-generation RNA cancer immunotherapies.
- **2023-09** — Secured a $3M NIH Phase II SBIR grant toward a pre-IND filing.
- **2023-01** — Launched a CEPI-funded benchmarking study of the RNABL platform for pandemic preparedness.

## Links

- Website: https://tiba.bio
- LinkedIn: https://www.linkedin.com/company/tiba-biotech

---

Profile page: https://yespress.io/tiba-biotech
Published by YesPress — https://yespress.io
Last updated: 2026-07-02